Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI
Why the study?
Does low-dose or very-low-dose rivaroxaban reduce clinically significant bleeding compared to standard vitamin K antagonist therapy in participants with atrial fibrillation undergoing PCI with stent placement?
Population
Participants with atrial fibrillation undergoing PCI with placement of stents
Comparison
Low-dose rivaroxaban plus a P2Y12 inhibitor for… vs Standard therapy with a vitamin K antagonist…
Design
RCT
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
Supports rivaroxaban regimens to lower bleeding versus VKA plus DAPT in AF-PCI; confirms modified therapy benefits in randomized data.
Structured PICO
Does low-dose or very-low-dose rivaroxaban reduce clinically significant bleeding compared to standard vitamin K antagonist therapy in participants with atrial fibrillation undergoing PCI with stent placement?
P
Population
Participants with atrial fibrillation undergoing PCI with placement of stents
I
Intervention
Low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months OR very-low-dose rivaroxaban plus DAPT for 1, 6, or 12 months
C
Comparator
Standard therapy with a vitamin K antagonist plus DAPT for 1, 6, or 12 months
O
Outcome
Clinically significant bleedingsafety
In patients with atrial fibrillation undergoing PCI, rivaroxaban-based antithrombotic regimens reduce clinically significant bleeding compared to standard vitamin K antagonist plus DAPT.
Limitations
- Broad confidence intervals diminish the surety of any conclusions regarding efficacy
Cite This Study
Gibson et al. (2016) studied this question.